Navigation Links
UBC researchers invent new drug delivery device to treat diabetes-related vision loss
Date:6/30/2011

zing water out of a flexible bottle.

In a series of lab tests, the UBC researchers loaded the implantable device with the drug docetaxel and triggered the drug release at a dosage suitable for treating diabetic retinopathy. They found that the implantable device kept its integrity with negligible leakage over 35 days.

They also monitored the drug's biological effectiveness over a given period, testing it against two types of cultured cancer cells, including those found in the prostate. They found that they were able to achieve reliable release rates.

"The docetaxel retained its pharmacological efficacy for more than two months in the device and was able to kill off the cancer cells," says Pirmoradi.

The UBC device offers improvements upon existing implantable devices for drug delivery, says Chiao.

"Technologies available now are either battery operated and are too large for treating the eye, or they rely on diffusion, which means drug release rates cannot be stopped once the device is implanted a problem when patients' conditions change."

Pirmoradi says it will be several years before the UBC device is ready for patient use. "There's a lot of work ahead of us in terms of biocompatibility and performance optimization."

The team is also working to pinpoint all the possible medical applications for their device so that they can tailor the mechanical design to particular diseases.


'/>"/>

Contact: Lorraine Chan
lorraine.chan@ubc.ca
604-822-2644
University of British Columbia
Source:Eurekalert

Page: 1 2

Related biology news :

1. NC State researchers get to root of parasite genome
2. Researchers find animal with ability to survive climate change
3. Researchers find an essential gene for forming ears of corn
4. Researchers note differences between people and animals on calorie restriction
5. Researchers study acoustic communication in deep-sea fish
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Researchers study how pistachios may improve heart health
8. UI researchers find potentially toxic substance present in Chicago air
9. Researchers develop new self-training gene prediction program for fungi
10. Case Western Reserve University researchers track Chernobyl fallout
11. Childrens National researchers develop novel anti-tumor vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... have discovered how two closely related proteins guide projections ... repelling these axons as they navigate the most miniscule ... remarkably precise connections. The discovery, reported April 28 ... belonging to the "semaphorin" family of guidance cues are ...
... As part of the Genome Canada Large-Scale Applied Research ... million to 16 projects across the country, the researchers ... function with the aim of identifying genes or proteins ... to target cancers and other diseases. The first ...
... by a parasitic fungus dramatically changes the behavior of tropical ... to become zombie-like and to die at a spot that ... team studied ants living high up in the rainforest canopy ... in the BioMed Central open-access journal BMC Ecology ...
Cached Biology News:Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3Zombie ants have fungus on the brain, new research reveals 2
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... Calif. , April 22, 2015 ... and analytics, announced today that it has opened ... its continued growth and expansion.  The common stock ... Act, Section 506(c), a law intended to encourage ... regulations.  Prior to 506(c), small businesses largely relied ...
(Date:4/22/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... to initiate a Phase 1 pharmacokinetic and biomarker ... Biohaven plans to initiate the trial no later ... in the Phase 1 study, Biohaven will move ...
Breaking Biology Technology:Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 2Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 3
... , , , , ... Inc.,(Nasdaq: SSRX ), a leading biotechnology company focused ... today announced that it has submitted its application for ... Drug,Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme ...
... , , ... enrollment of patients with acute ischemic stroke into its,Phase III ... at the Wolfson Medical Center, Israel. The MACSI trial involves,numerous ... Korea and Brazil. DP-b99 is D-Pharm,s most advanced product developed,for ...
... WASHINGTON, Dec. 29 The National Fragile X Foundation applauds ... Fragile X Syndrome for the first time ever within a ... U.S. Department of Defense. , The new law, ... through the FY 2010 Department of Defense Appropriations Act for ...
Cached Biology Technology:3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3Defense Department to Support Fragile X Research 2